BR112015000449A2 - - Google Patents
Info
- Publication number
- BR112015000449A2 BR112015000449A2 BR112015000449A BR112015000449A BR112015000449A2 BR 112015000449 A2 BR112015000449 A2 BR 112015000449A2 BR 112015000449 A BR112015000449 A BR 112015000449A BR 112015000449 A BR112015000449 A BR 112015000449A BR 112015000449 A2 BR112015000449 A2 BR 112015000449A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12305821.6 | 2012-07-09 | ||
EP12305821.6A EP2684896A1 (en) | 2012-07-09 | 2012-07-09 | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
US201261669866P | 2012-07-10 | 2012-07-10 | |
US61/669,866 | 2012-07-10 | ||
PCT/EP2013/064466 WO2014009358A1 (en) | 2012-07-09 | 2013-07-09 | Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015000449A2 true BR112015000449A2 (pt) | 2017-08-15 |
BR112015000449B1 BR112015000449B1 (pt) | 2022-12-20 |
Family
ID=46514282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015000449-0A BR112015000449B1 (pt) | 2012-07-09 | 2013-07-09 | Anticorpos da família anti-dr5, anticorpos da família anti-dr5 multivalentes ou biespecíficos e métodos de uso dos mesmos |
Country Status (16)
Country | Link |
---|---|
US (4) | US9611327B2 (pt) |
EP (3) | EP2684896A1 (pt) |
JP (1) | JP6457386B2 (pt) |
CN (1) | CN104619725B (pt) |
BR (1) | BR112015000449B1 (pt) |
CA (1) | CA2878790C (pt) |
DK (1) | DK2877491T3 (pt) |
ES (1) | ES2727486T3 (pt) |
HK (1) | HK1211044A1 (pt) |
IL (2) | IL236651B (pt) |
IN (1) | IN2015DN00143A (pt) |
PL (1) | PL2877491T3 (pt) |
PT (1) | PT2877491T (pt) |
SG (2) | SG10201700148UA (pt) |
SI (1) | SI2877491T1 (pt) |
WO (1) | WO2014009358A1 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3750918A1 (en) | 2015-01-20 | 2020-12-16 | IGM Biosciences, Inc. | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
EP3048116A1 (en) | 2015-01-23 | 2016-07-27 | International-Drug-Development-Biotech | Anti-dr5 antibodies with enhanced apoptosis potency |
SG11201706024YA (en) | 2015-01-26 | 2017-08-30 | Macrogenics Inc | Multivalent molecules comprising dr5-binding domains |
EP3112381A1 (en) * | 2015-07-01 | 2017-01-04 | FONDAZIONE IRCCS Istituto Nazionale dei Tumori | Bispecific antibodies for use in cancer immunotherapy |
HUE051896T2 (hu) * | 2015-07-16 | 2021-03-29 | Inhibrx Inc | Multivalens és multispecifikus DR5-kötõ fúziós fehérjék |
NZ743316A (en) * | 2015-12-01 | 2023-12-22 | Genmab Bv | Anti-dr5 antibodies and methods of use thereof |
CN106397594B (zh) * | 2016-10-25 | 2019-06-04 | 中国药科大学 | 一种全人源的抗人死亡受体5的激动剂单链抗体及应用 |
EP3535291A1 (en) | 2016-11-01 | 2019-09-11 | Genmab B.V. | Polypeptide variants and uses thereof |
EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
CA3053222A1 (en) | 2017-02-10 | 2018-08-16 | Genmab B.V. | Polypeptide variants and uses thereof |
KR101926834B1 (ko) * | 2017-03-21 | 2018-12-07 | 동아에스티 주식회사 | 항-dr5 항체 및 그의 용도 |
US20200247897A1 (en) | 2017-06-07 | 2020-08-06 | Genmab B.V. | Therapeutic antibodies based on mutated igg hexamers |
US20210107988A1 (en) | 2018-01-24 | 2021-04-15 | Genmab B.V. | Polypeptide variants and uses thereof |
US20200392239A1 (en) * | 2018-02-26 | 2020-12-17 | Igm Biosciences, Inc. | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
SG11202010601VA (en) | 2018-05-03 | 2020-11-27 | Genmab Bv | Antibody variant combinations and uses thereof |
WO2020225456A1 (en) | 2019-05-09 | 2020-11-12 | Genmab B.V. | Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer |
EP4055046A1 (en) | 2019-11-06 | 2022-09-14 | Genmab B.V. | Antibody variant combinations and uses thereof |
JP2023534726A (ja) | 2020-07-23 | 2023-08-10 | ジェンマブ ビー.ブイ. | 多発性骨髄腫の治療に使用するための抗dr5抗体と免疫調節イミド薬との併用 |
WO2023168364A2 (en) * | 2022-03-02 | 2023-09-07 | Walden Biosciences, Inc. | Novel soluble urokinase plasminogen activator receptor (supar) binding molecules and uses thereof |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6284236B1 (en) | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
WO1997037020A1 (en) | 1996-04-01 | 1997-10-09 | Genentech, Inc. | Apo-2li and apo-3 apoptosis polypeptides |
PT1012274E (pt) | 1997-01-28 | 2007-08-14 | Craig A Rosen | Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02) |
US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
US20050233958A1 (en) | 1997-03-17 | 2005-10-20 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
CA2318029C (en) * | 1998-01-15 | 2009-05-19 | Genentech, Inc. | Apo-2 ligand |
DE69922159T2 (de) | 1998-01-23 | 2005-12-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Mehrzweck-antikörperderivate |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
ES2267547T3 (es) | 1999-06-09 | 2007-03-16 | Genentech, Inc. | Sinergia de antagonista de receptores del ligando apo-2l y de cpt-11. |
US6444640B1 (en) | 1999-09-30 | 2002-09-03 | Ludwig Institute For Cancer Research | Compositions of trail and DNA damaging drugs and uses thereof |
US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
GB0020442D0 (en) | 2000-08-18 | 2000-10-04 | Nokia Networks Oy | Data transmission protocol |
US20020155109A1 (en) | 2001-04-20 | 2002-10-24 | Lynch David H. | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 |
MXPA03010747A (es) | 2001-05-25 | 2004-03-02 | Human Genome Sciences Inc | Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral. |
ATE433996T1 (de) | 2001-07-03 | 2009-07-15 | Genentech Inc | Humane dr4-antikörper und deren anwendungen |
KR20070010046A (ko) * | 2004-04-06 | 2007-01-19 | 제넨테크, 인크. | Dr5 항체 및 그의 용도 |
CA2587766A1 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
WO2006093794A1 (en) | 2005-02-28 | 2006-09-08 | Centocor, Inc. | Heterodimeric protein binding compositions |
WO2007106707A2 (en) | 2006-03-10 | 2007-09-20 | Macrogenics, Inc. | Identification and engineering of antibodies with variant heavy chains and methods of using same |
KR100847010B1 (ko) * | 2006-07-05 | 2008-07-17 | 아주대학교산학협력단 | 세포사멸 수용체 5 (dr5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물 |
WO2009002947A2 (en) | 2007-06-22 | 2008-12-31 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
-
2012
- 2012-07-09 EP EP12305821.6A patent/EP2684896A1/en not_active Withdrawn
-
2013
- 2013-07-09 EP EP13734785.2A patent/EP2877491B1/en active Active
- 2013-07-09 JP JP2015520954A patent/JP6457386B2/ja active Active
- 2013-07-09 SG SG10201700148UA patent/SG10201700148UA/en unknown
- 2013-07-09 DK DK13734785.2T patent/DK2877491T3/da active
- 2013-07-09 BR BR112015000449-0A patent/BR112015000449B1/pt active IP Right Grant
- 2013-07-09 EP EP19159204.7A patent/EP3575323B1/en active Active
- 2013-07-09 IN IN143DEN2015 patent/IN2015DN00143A/en unknown
- 2013-07-09 WO PCT/EP2013/064466 patent/WO2014009358A1/en active Application Filing
- 2013-07-09 SI SI201331443T patent/SI2877491T1/sl unknown
- 2013-07-09 CN CN201380036952.2A patent/CN104619725B/zh active Active
- 2013-07-09 SG SG11201500177PA patent/SG11201500177PA/en unknown
- 2013-07-09 PT PT13734785T patent/PT2877491T/pt unknown
- 2013-07-09 ES ES13734785T patent/ES2727486T3/es active Active
- 2013-07-09 CA CA2878790A patent/CA2878790C/en active Active
- 2013-07-09 US US14/413,194 patent/US9611327B2/en active Active
- 2013-07-09 PL PL13734785T patent/PL2877491T3/pl unknown
-
2015
- 2015-01-11 IL IL23665115A patent/IL236651B/en active IP Right Grant
- 2015-12-03 HK HK15111900.9A patent/HK1211044A1/xx unknown
-
2017
- 2017-02-17 US US15/436,583 patent/US10647774B2/en active Active
-
2019
- 2019-09-22 IL IL269527A patent/IL269527B/en unknown
-
2020
- 2020-04-06 US US16/841,306 patent/US20200332016A1/en not_active Abandoned
-
2023
- 2023-09-06 US US18/461,910 patent/US20240141057A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL269527B (en) | 2021-12-01 |
EP2684896A1 (en) | 2014-01-15 |
CN104619725A (zh) | 2015-05-13 |
IL269527A (en) | 2019-11-28 |
CA2878790A1 (en) | 2014-01-16 |
US20240141057A1 (en) | 2024-05-02 |
IL236651A0 (en) | 2015-02-26 |
US9611327B2 (en) | 2017-04-04 |
US20200332016A1 (en) | 2020-10-22 |
US20170260281A1 (en) | 2017-09-14 |
EP3575323B1 (en) | 2024-09-11 |
SG10201700148UA (en) | 2017-02-27 |
HK1211044A1 (en) | 2016-05-13 |
EP3575323A1 (en) | 2019-12-04 |
JP2015527992A (ja) | 2015-09-24 |
JP6457386B2 (ja) | 2019-01-23 |
EP2877491B1 (en) | 2019-02-27 |
IL236651B (en) | 2019-10-31 |
IN2015DN00143A (pt) | 2015-06-12 |
WO2014009358A1 (en) | 2014-01-16 |
SG11201500177PA (en) | 2015-03-30 |
US20150139997A1 (en) | 2015-05-21 |
ES2727486T3 (es) | 2019-10-16 |
PL2877491T3 (pl) | 2020-01-31 |
PT2877491T (pt) | 2019-06-07 |
US10647774B2 (en) | 2020-05-12 |
SI2877491T1 (sl) | 2019-08-30 |
BR112015000449B1 (pt) | 2022-12-20 |
EP2877491A1 (en) | 2015-06-03 |
CN104619725B (zh) | 2019-04-23 |
CA2878790C (en) | 2023-09-26 |
DK2877491T3 (da) | 2019-06-03 |
Similar Documents
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: INTERNATIONAL - DRUG - DEVELOPMENT - BIOTECH (FR) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: GENMAB HOLDING B.V. (NL) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B25A | Requested transfer of rights approved |
Owner name: GENMAB B.V. (NL) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/07/2013, OBSERVADAS AS CONDICOES LEGAIS |